Mitek Sports Medicine expands early intervention options for sports medicine physicians and patients

Company Expands Early Intervention Platform to Include Single Injection Hyaluronic Acid and Innovative Platelet Rich Plasma (PRP) System

Mitek Sports Medicine, a leader in orthopaedics sports medicine and a part of the DePuy Synthes Companies of Johnson & Johnson, announced the launch of MONOVISC^® High Molecular Weight Hyaluronan, a single-injection treatment for knee pain related to osteoarthritis and the PEAK™ Platelet Rich Plasma (PRP) System, a new device that produces high quality PRP in only 2.5 minutes.

The announcement was made here at the American Orthopaedic Society for Sports Medicine (AOSSM) 2014 Annual Meeting, where Mitek Sports Medicine is featuring innovations along a spectrum of care to help sports medicine specialists provide personalized treatment for joint injuries related to sports and physical activity, as well as degenerative tissue conditions.

“Both products are important new early intervention options for sports medicine physicians and their patients,” said Peter Vitanzo, MD, Sports Medicine Specialist at the Rothman Institute in Philadelphia. “These products give us more non-operative tools to personalize the approach for the individual patient based on their level of activity, degree of injury and treatment preference.”

MONOVISC

MONOVISC is a single-injection hyaluronan treatment that can provide up to six months of pain relief and helps restore joint mobility in patients suffering from pain associated with osteoarthritis of the knee. It is injected directly into the knee to help replace the naturally occuring hyaluronan found in healthy joint fluid, and to cushion, protect and lubricate the knee joint.

MONOVISC is for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics such as acetaminophen. MONOVISC is the only single-injection treatment with hyaluronic acid produced from a non-avian source, thereby reducing the risk for allergic reaction in some patients.

Mitek Sports Medicine is the exclusive marketer and distributor of MONOVISC and ORTHOVISC^® High Molecular Weight Hyaluronan, a multi-injection hyaluronan treatment also used to treat knee pain due to osteoarthritis. According to the AOSSM, osteoarthritis is the most common type of arthritis, affecting nearly 20 million Americans.

PEAK PRP System

Mitek Sports Medicine is the exclusive marketer and distributor of the PEAK PRP System, which works by separating PRP from a sample of a patient’s own blood. The device consistently produces 3mL of high quality PRP from 27mL of whole blood in 2.5 minutes, yielding up to seven-times the normal concentration of platelets. The processing time is significantly less than competitor systems that have processing times ranging from 10 to 30 minutes. In addition, the PEAK PRP System weighs only four pounds, making it smaller and more portable.

“Our goal with these single- and multiple-injection products, and our new PRP system, is to provide a range of options across the sports medicine patient continuum of care that help return patients to the activities they enjoy as quickly as possible,” said Ian Lawson, Worldwide President, Mitek Sports Medicine.